Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025649
pages 137-181

Long-Acting Injectables: Current Perspectives and Future Promise

Komal Chaudhary
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Mayur M. Patel
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Priti J. Mehta
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India

RESUMO

The parenteral route of administration is preferred over the oral route for treatment of many chronic and life-threatening diseases due to better patient compliance. Long-acting injectables/depot delivery systems are formulations intended for prolonged/sustained drug release over a long period of time ranging from a few days to months. Depot delivery systems enhance product quality by decreasing dosing frequency, simplifying the drug regimen. Parenteral depots reduce the relapse rate of disease and the maintenance phase of therapy, hence improving efficacy and treatment adherence. However, despite being extensively explored in the last seventy years, only a few depot products have been marketed or have reached commercial viability. The introduction of long-acting injectables of any drug took 9 to 10 years after approval of its oral formulation. Mainly the market has been conquered by long-acting injectables for antipsychotic, substance abuse, and hormonal therapy drugs.
This article focuses on the preparation of long-acting injectables with special emphasis on challenges associated with formulation. The evolution and current global market trend of various depot formulations are also discussed. Insight is provided into the promising future of long-acting injectables of protein-based drugs as well as multidrug therapy, along with potential uses in the treatment of chronic diseases like HIV, Parkinson's, and Alzheimer's.


Articles with similar content:

Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 6
Wei Zhang, Arunprasad Sivaraman, Meredith R. Clark, Ajay K. Banga, Ashana Puri
Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 1
Niyati S. Acharya, Namdev L. Dhas, Ritu R. Kudarha, Sanjeev R. Acharya
Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst
Submicron Emulsions and Their Applications in Oral Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 3
Veenu Mundada, Krutika Sawant, Mitali Patel
Rehabilitation in Multiple Sclerosis
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.10, 1998, issue 1
Agnete Jonsson, Mads H. Ravnborg